Recognized as one of the most promising breakthroughs in the field of metabolic health , Retatrutide offers a comprehensive approach to weight management
GLP-1RA are currently being studied in phase 3 trials for the treatment of HFpEF, peripheral artery disease (PAD), diabetic kidney disease (DKD), metabolic liver disorders such as nonalcoholic steatohepatitis (NASH), and neurodegenerative disorders
Further, a clinical trial of over 3,000 people living with type 2 diabetes and chronic kidney disease found that semaglutide led to improvement for kidney, cardiovascular, and survival outcomes including a 24% reduced risk of kidney disease events and18% lower risk of major cardiovascular events compared to placebo
Hemoglobin A1C: This test measures your average blood sugar over the previous 2 to 3 months
Let us help you unlock your best self with the help of science.
In a rigorous clinical trial, the Southwest Oncology Group SWOG-8897 found that the MPO genotype of breast cancer patients undergoing chemotherapy was associated with a lower risk of recurrence, and a high-activity MPO genotype was related to a higher survival rate among women treated with cyclophosphamide [129]
